PubSum makes scientific literature accessible to everyone. Get instant AI-powered summaries of research articles through PubMed search or PDF upload. Save hours on literature reviews while ensuring no important findings are missed.
Evaluates safety and efficacy of BNT162b2 mRNA vaccine...
β’ 95% efficacy in preventing Covid-19
β’ Consistent across all age groups
Highly effective and safe for widespread use...
Three simple steps to transform complex research into accessible knowledge
Enter a DOI, PMID, or PMCID to search PubMed, or upload your scientific PDF directly
Our advanced AI extracts and analyzes the full text, identifying key findings and insights
Receive structured technical summaries and simplified non-scientific versions quickly
Seamlessly search and summarize articles using DOI, PMID, or PMCID identifiers
Upload any scientific PDF for instant processing, even unpublished manuscripts
Get organized sections: Main Subject, Aim, Key Findings, Implications, and more
Make complex research accessible to non-academic populations with simplified explanations
Automatically identify and highlight quantitative data and specific research outcomes
Get comprehensive summaries quickly, saving hours of reading time
Estimated pricing for when we exit beta
Pricing is subject to change prior to launch
15 summaries per month
60 summaries per month
250 summaries per month
Credits never expire - use them at your own pace
Experience how PubSum transforms dense scientific literature into clear, structured insights
The study evaluates the safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine in preventing Covid-19 in individuals aged 16 years or older.
The trial aimed to assess whether the BNT162b2 vaccine (two 30-ΞΌg doses, 21 days apart) is safe and effective against laboratory-confirmed Covid-19 compared to placebo.
1. The vaccine showed 95% efficacy (95% CI, 90.3β97.6) in preventing Covid-19, with 8 cases in the vaccine group vs. 162 in the placebo group 7 days after the second dose.
2. Efficacy was consistent across subgroups (age, sex, race, obesity, comorbidities), ranging from 90β100%.
3. Severe Covid-19 occurred in 1 vaccine recipient vs. 9 placebo recipients.
4. Safety profile included mild-to-moderate injection-site pain (71β83%), fatigue (51β59%), and headache (39β52%), with low rates of severe adverse events (β€2%).
The BNT162b2 vaccine is highly effective and safe, supporting its use for widespread immunization to curb the Covid-19 pandemic. Its efficacy across diverse populations underscores its broad applicability.
β’ Limited long-term safety data (median 2 months follow-up).
β’ Excluded immunocompromised individuals and those with prior Covid-19.
β’ Future research should assess durability of immunity, efficacy in younger age groups (<16 years), and real-world effectiveness.
β’ Design: Multinational, randomized, placebo-controlled, observer-blinded phase 2/3 trial.
β’ Participants: 43,448 individuals (21,720 vaccine, 21,728 placebo) aged β₯16 years.
β’ Measurements: Primary endpoints were vaccine efficacy against confirmed Covid-19 and safety (local/systemic reactogenicity, adverse events).
β’ Key Metrics: PCR-confirmed Covid-19 cases, severe disease incidence, and adverse event rates.
Scientists explored whether the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) was safe and effective in a large global trial involving over 43,000 volunteers aged 16+. Participants received either two vaccine doses or a placebo (dummy shot) three weeks apart, without knowing which they got. The vaccine was 95% effective at preventing COVID-19 symptomsβonly 8 vaccinated people got sick compared to 162 in the placebo group, with similar protection across ages, races, and health conditions. Side effects like arm pain, fatigue, and headache were mostly mild and short-lived, occurring more often after the second dose but remaining less severe than in many common vaccines. Importantly, the vaccine prevented nearly all severe COVID-19 cases (9 in placebo vs. 1 in vaccinated). These results, monitored for two months post-vaccination, showed the shots were both highly protective and safe, offering a practical tool to control the pandemic. The study's rigorβrandomized, double-blind, and diverseβgave confidence that the benefits far outweighed temporary discomfort for most people.
Accelerate literature reviews and stay updated on the latest findings in your field
Understand complex papers and develop research comprehension skills
Create accessible teaching materials from cutting-edge research
Quickly grasp research findings to create accurate, engaging content
Join thousands of researchers, non-academic users, and educators who are saving time and gaining deeper insights with PubSum.